Multicenter Quantitative MRI Assessment of Breast Cancer Therapy Response

项目摘要 肿瘤生物学功能的定量成像在以下方面显示出优于肿瘤大小的成像 癌症治疗反应的预测和评估。常规用作非侵入性成像 评价微血管血流灌注和通透性的方法，动态增强磁共振成像(DCE)是 越来越多地在研究和早期临床试验环境中使用，以测量并预测(重要的是) 肿瘤对治疗的反应。标准的两参数或三参数Tofts模型(TM)是最多的 通常用于DCE-MRI数据的药代动力学(PK)建模以估计定量成像 生物标志物，如KTRANS和VE。然而，TM是次优的，因为它忽略了真正的生理 定量组织浓度时组织间的水交换现象 造影剂来自MRI信号强度。俄勒冈健康中心开发的快门速度模型(SSM) &Science University(OHSU)群是一种更全面的PK模式，考虑到 隔间水交换动力学。最近的单中心OHSU研究表明， SSM DCE-MRI预测和评价乳腺癌治疗反应的能力 TM.此外，最近还发现，SSM排斥参数τI(平均细胞内水分 寿命)，是一种新的代谢活动的成像生物标志物，也是唯一的基线(治疗前)标志物 预测乳腺癌对新辅助化疗(NAC)的反应和头颈部和外周血中的总生存率 颈癌。τI还具有对动脉输入功能变化的敏感度显著降低的优势 (AIF)比传统的PK参数。使用数据采集和分析协议 OHSU小组，这个项目的总体目标是验证SSM DCE-MRI作为定量的 多中心环境下前瞻性研究中癌症治疗反应的影像评估工具 跨三大MRI扫描平台，使用NAC治疗乳腺癌作为测试临床 申请。具体地说，我们将(1)实现优化的SSM DCE-MRI数据采集和分析 在多中心环境下进行QA/QC；(2)进行多中心前瞻性研究 SSM DCE-MRI在预测和评估乳腺癌对NAC的疗效中的作用；以及(3)提炼和分析 OHSU开发基于Web的临床决策支持系统，通过开发和整合预测 将影像标记物与临床和组织病理学数据相结合的治疗反应模型，以及 评估系统在临床工作流程中的适应性。

Project Summary Quantitative imaging of tumor biological functions have been shown superior to imaging tumor size for prediction and evaluation of cancer response to therapy. Conventionally used as a noninvasive imaging method to assess microvascular perfusion and permeability, dynamic contrast-enhanced (DCE) MRI is increasingly employed in research and early phase clinical trial settings to measure and, importantly, predict tumor response to treatment. The standard two- or three-parameter Tofts models (TMs) are the most commonly used for pharmacokinetic (PK) modeling of DCE-MRI data to estimate quantitative imaging biomarkers such as Ktrans and ve. However, the TM is suboptimal in that it ignores the real physiological phenomenon of water exchange between tissue compartments when quantifying tissue concentration of contrast agent from MRI signal intensities. The Shutter-Speed Model (SSM) developed by the Oregon Health & Science University (OHSU) group is a more comprehensive PK model, taking into account the intercompartmental water exchange kinetics. Recent single-center OHSU studies have demonstrated superior ability of SSM DCE-MRI for prediction and evaluation of therapy response in breast cancer compared to the TM. Furthermore, it was recently discovered that the SSM-exclusive parameter, τi (mean intracellular water lifetime), is a new imaging biomarker of metabolic activity, and was the only baseline (pre-treatment) marker predictive of response to neoadjuvant chemotherapy (NAC) in breast cancer and overall survival in head and neck cancer. τi also has the advantage of being significantly less sensitive to variation in arterial input function (AIF) than the conventional PK parameters. Using the data acquisition and analysis protocols optimized by the OHSU group, the overall goal of this project is to validate the robustness of SSM DCE-MRI as a quantitative imaging tool for assessment of cancer therapy response in a prospective study under a multicenter setting across three major MRI scanner platforms, using NAC treatment of breast cancer as the testing clinical application. Specifically, we will (1) implement the optimized SSM DCE-MRI data acquisition and analysis protocols and perform QA/QC in a multicenter setting; (2) conduct the multicenter prospective study to validate the utility of SSM DCE-MRI for prediction and evaluation of breast cancer response to NAC; and (3) refine an OHSU-developed web-based clinical decision support system by developing and incorporating a predictive model of therapy response that integrates imaging markers with clinical and histopathological data, and evaluate the system adaptability in clinical workflow.